Here’s our Club Mailbag email investingclubmailbag@cnbc.com — so you send your questions directly to Jim Cramer and his team of analysts. We can’t offer personal investing advice. We will only consider more general questions about the investment process or stocks in the portfolio or related industries. This week’s question: I …
The U.S. presidential election beckons and even though nearly 75 million people have already voted, according to NBC News , nothing seems to have leaked out. You would figure the hedge fund algorithms would have picked up something by now, but I haven’t seen any confirmed bets made either way. …
Bristol Myers Squibb’s Cobenfy drug Courtesy: Bristol Myers Squibb The Food and Drug Administration on Thursday approved Bristol Myers Squibb‘s highly anticipated schizophrenia drug Cobenfy, the first novel type of treatment for the debilitating, chronic mental disorder in more than seven decades. Schizophrenia affects how a person thinks, feels and …
Drugmakers are betting that delivering radiation directly to tumors will become the next big cancer breakthrough. Bristol Myers Squibb, AstraZeneca, Eli Lilly and other pharmaceutical companies have spent some $10 billion on deals to acquire or work with radiopharmaceuticals makers. They’ve snapped up smaller upstarts to get their hands on …
Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services building in Washington, D.C., on Oct. 6, 2022. Anna Moneymaker | Getty Images The Biden administration on Thursday released prices for the first 10 prescription drugs that were subject to landmark …
It didn’t take long to remember what a second Donald Trump presidential term would mean for the stock market, did it? Unpredictability. Random attacks. No one safe. Mercurial positions. The only difference? Former Vice President Mike Pence meant nothing. He was supposed to mean nothing. Now the Republican candidate’s new …
Kena Betancur | Corbis News | Getty Images Pfizer had a “phenomenal” first quarter — and Wall Street took notice, CEO Albert Bourla told thousands of employees during a companywide town hall on May 2, according to a recording heard by CNBC. A day earlier, the pharmaceutical giant’s stock had …
Attendees walk through the lobby at the American Society of Clinical Oncology annual meeting in Chicago. Tim Boyle | Bloomberg | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! I’m back in New York City after …
Skynesher | E+ | Getty Images Big pharma is betting billions on an up-and-coming class of cancer treatments that some on Wall Street are calling a “massive opportunity.” It’s called targeted radiopharmaceutical therapy. It essentially delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule. RBC …
There’s been a lot of attention lately on a corner of the oncology market called radiopharmaceuticals. The therapy seeks to destroy cancer cells by binding a radioactive particle to a targeted molecule and then dispatching it directly into the tumor. There are currently two products on the market from Novartis …